Ocular Deferred Long Term Liab vs Net Tangible Assets Analysis

OCUL Stock

USD 6.77 0.04 0.59%

Ocular Therapeutix financial indicator trend analysis is much more than just breaking down Ocular Therapeutix prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ocular Therapeutix is a good investment. Please check the relationship between Ocular Therapeutix Deferred Long Term Liab and its Net Tangible Assets accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

Deferred Long Term Liab vs Net Tangible Assets

Deferred Long Term Liab vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ocular Therapeutix Deferred Long Term Liab account and Net Tangible Assets. At this time, the significance of the direction appears to have very week relationship.

The correlation between Ocular Therapeutix's Deferred Long Term Liab and Net Tangible Assets is 0.25. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Ocular Therapeutix, assuming nothing else is changed. The correlation between historical values of Ocular Therapeutix's Deferred Long Term Liab and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Ocular Therapeutix are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Deferred Long Term Liab i.e., Ocular Therapeutix's Deferred Long Term Liab and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.25

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from Ocular Therapeutix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ocular Therapeutix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.Selling General Administrative is expected to rise to about 41 M this year, although the value of Issuance Of Capital Stock will most likely fall to about 8.1 M.

	2022	2023	2024	2025 (projected)
Interest Expense	7.0M	11.3M	13.0M	13.7M
Depreciation And Amortization	2.1M	3.0M	3.4M	3.6M

Interest Expense Depreciation And Amortization

Ocular Therapeutix fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.92	0.92	0.94	0.84	0.62	0.82	-0.87	-0.89	0.7	0.98	0.68	0.2	0.13	0.91	0.99	0.91	0.93	0.78	0.97	0.95	0.85	0.86	1.0	0.16	0.6
Short Long Term Debt Total	0.92		0.96	0.96	0.72	0.47	0.96	-0.69	-0.95	0.8	0.91	0.82	0.28	0.04	0.99	0.87	0.93	0.97	0.76	0.9	0.98	0.84	0.94	0.9	-0.07	0.61
Other Current Liab	0.92	0.96		0.98	0.71	0.36	0.89	-0.69	-0.92	0.77	0.9	0.73	0.23	-0.08	0.97	0.87	0.99	0.96	0.75	0.9	0.96	0.83	0.95	0.9	-0.12	0.52
Total Current Liabilities	0.94	0.96	0.98		0.73	0.5	0.92	-0.77	-0.95	0.81	0.94	0.77	0.24	0.04	0.95	0.9	0.97	0.97	0.78	0.93	0.98	0.86	0.92	0.93	-0.04	0.56
Total Stockholder Equity	0.84	0.72	0.71	0.73		0.4	0.64	-0.64	-0.71	0.69	0.73	0.57	0.29	0.14	0.73	0.85	0.67	0.78	0.32	0.77	0.79	0.43	0.66	0.84	0.32	0.86
Other Liab	0.62	0.47	0.36	0.5	0.4		0.44	-0.83	-0.56	0.33	0.69	0.45	0.13	0.64	0.39	0.66	0.4	0.47	0.66	0.63	0.5	0.65	0.28	0.63	0.41	0.32
Property Plant And Equipment Net	0.82	0.96	0.89	0.92	0.64	0.44		-0.6	-0.94	0.86	0.82	0.92	0.42	0.17	0.94	0.76	0.84	0.94	0.66	0.81	0.94	0.75	0.9	0.79	-0.07	0.66
Net Debt	-0.87	-0.69	-0.69	-0.77	-0.64	-0.83	-0.6		0.75	-0.5	-0.92	-0.53	-0.16	-0.35	-0.66	-0.89	-0.74	-0.72	-0.81	-0.89	-0.75	-0.83	-0.61	-0.88	-0.22	-0.38
Retained Earnings	-0.89	-0.95	-0.92	-0.95	-0.71	-0.56	-0.94	0.75		-0.89	-0.89	-0.9	-0.38	-0.21	-0.94	-0.84	-0.9	-0.97	-0.71	-0.9	-0.97	-0.79	-0.85	-0.87	0.01	-0.65
Accounts Payable	0.7	0.8	0.77	0.81	0.69	0.33	0.86	-0.5	-0.89		0.66	0.92	0.45	0.17	0.8	0.64	0.74	0.87	0.38	0.72	0.85	0.49	0.7	0.67	0.01	0.76
Cash	0.98	0.91	0.9	0.94	0.73	0.69	0.82	-0.92	-0.89	0.66		0.69	0.22	0.19	0.89	0.97	0.91	0.91	0.87	0.97	0.93	0.92	0.85	0.98	0.08	0.5
Non Current Assets Total	0.68	0.82	0.73	0.77	0.57	0.45	0.92	-0.53	-0.9	0.92	0.69		0.59	0.36	0.81	0.62	0.68	0.83	0.5	0.68	0.83	0.58	0.74	0.64	-0.06	0.68
Non Currrent Assets Other	0.2	0.28	0.23	0.24	0.29	0.13	0.42	-0.16	-0.38	0.45	0.22	0.59		0.68	0.3	0.16	0.14	0.36	0.0	0.22	0.36	0.05	0.27	0.16	-0.17	0.48
Other Assets	0.13	0.04	-0.08	0.04	0.14	0.64	0.17	-0.35	-0.21	0.17	0.19	0.36	0.68		-0.01	0.15	-0.11	0.1	0.08	0.13	0.13	0.07	-0.1	0.11	0.27	0.33
Long Term Debt	0.91	0.99	0.97	0.95	0.73	0.39	0.94	-0.66	-0.94	0.8	0.89	0.81	0.3	-0.01		0.86	0.94	0.97	0.73	0.89	0.97	0.81	0.95	0.89	-0.11	0.61
Cash And Short Term Investments	0.99	0.87	0.87	0.9	0.85	0.66	0.76	-0.89	-0.84	0.64	0.97	0.62	0.16	0.15	0.86		0.87	0.88	0.77	0.95	0.91	0.83	0.81	1.0	0.23	0.59
Net Receivables	0.91	0.93	0.99	0.97	0.67	0.4	0.84	-0.74	-0.9	0.74	0.91	0.68	0.14	-0.11	0.94	0.87		0.95	0.79	0.92	0.94	0.87	0.9	0.91	-0.11	0.44
Common Stock Shares Outstanding	0.93	0.97	0.96	0.97	0.78	0.47	0.94	-0.72	-0.97	0.87	0.91	0.83	0.36	0.1	0.97	0.88	0.95		0.7	0.93	0.99	0.79	0.9	0.91	-0.02	0.66
Non Current Liabilities Total	0.78	0.76	0.75	0.78	0.32	0.66	0.66	-0.81	-0.71	0.38	0.87	0.5	0.0	0.08	0.73	0.77	0.79	0.7		0.8	0.72	0.99	0.72	0.78	-0.05	0.05
Other Current Assets	0.97	0.9	0.9	0.93	0.77	0.63	0.81	-0.89	-0.9	0.72	0.97	0.68	0.22	0.13	0.89	0.95	0.92	0.93	0.8		0.93	0.86	0.82	0.96	0.07	0.53
Other Stockholder Equity	0.95	0.98	0.96	0.98	0.79	0.5	0.94	-0.75	-0.97	0.85	0.93	0.83	0.36	0.13	0.97	0.91	0.94	0.99	0.72	0.93		0.81	0.92	0.93	0.02	0.67
Total Liab	0.85	0.84	0.83	0.86	0.43	0.65	0.75	-0.83	-0.79	0.49	0.92	0.58	0.05	0.07	0.81	0.83	0.87	0.79	0.99	0.86	0.81		0.8	0.85	-0.05	0.17
Property Plant And Equipment Gross	0.86	0.94	0.95	0.92	0.66	0.28	0.9	-0.61	-0.85	0.7	0.85	0.74	0.27	-0.1	0.95	0.81	0.9	0.9	0.72	0.82	0.92	0.8		0.84	-0.16	0.49
Total Current Assets	1.0	0.9	0.9	0.93	0.84	0.63	0.79	-0.88	-0.87	0.67	0.98	0.64	0.16	0.11	0.89	1.0	0.91	0.91	0.78	0.96	0.93	0.85	0.84		0.18	0.58
Short Term Debt	0.16	-0.07	-0.12	-0.04	0.32	0.41	-0.07	-0.22	0.01	0.01	0.08	-0.06	-0.17	0.27	-0.11	0.23	-0.11	-0.02	-0.05	0.07	0.02	-0.05	-0.16	0.18		0.25
Common Stock	0.6	0.61	0.52	0.56	0.86	0.32	0.66	-0.38	-0.65	0.76	0.5	0.68	0.48	0.33	0.61	0.59	0.44	0.66	0.05	0.53	0.67	0.17	0.49	0.58	0.25

Click cells to compare fundamentals

Ocular Therapeutix Account Relationship Matchups

Ocular Therapeutix fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	261.9M	204.9M	149.3M	252.1M	289.9M	304.4M
Short Long Term Debt Total	58.4M	59.0M	64.3M	83.4M	95.9M	100.7M
Other Current Liab	12.9M	18.5M	22.5M	28.7M	33.0M	34.6M
Total Current Liabilities	26.7M	26.3M	31.4M	34.9M	40.1M	42.1M
Total Stockholder Equity	76.1M	88.0M	35.4M	91.1M	104.8M	110.0M
Other Liab	12.1M	110.3M	33.2M	19.8M	22.8M	18.3M
Property Plant And Equipment Net	13.9M	11.8M	17.9M	18.2M	20.9M	22.0M
Net Debt	(169.6M)	(105.2M)	(38.0M)	(112.4M)	(101.2M)	(96.1M)
Retained Earnings	(539.3M)	(545.8M)	(616.8M)	(697.6M)	(627.8M)	(596.4M)
Accounts Payable	2.7M	4.6M	5.1M	4.4M	5.0M	3.0M
Cash	228.1M	164.2M	102.3M	195.8M	225.2M	236.4M
Non Current Assets Total	15.7M	13.6M	19.7M	19.8M	22.8M	11.8M
Other Assets	6.6M	1.8M	7.6M	1.0	1.15	1.09
Long Term Debt	41.2M	51.4M	54.0M	74.9M	86.2M	90.5M
Cash And Short Term Investments	228.1M	164.2M	102.3M	195.8M	225.2M	236.4M
Net Receivables	12.3M	21.1M	21.3M	26.2M	30.1M	31.6M
Common Stock Shares Outstanding	60.8M	82.2M	76.9M	85.6M	98.4M	103.4M
Liabilities And Stockholders Equity	261.9M	204.9M	149.3M	252.1M	289.9M	304.4M
Non Current Liabilities Total	159.1M	90.6M	82.5M	126.0M	144.9M	152.2M
Other Current Assets	8.0M	9.5M	4.0M	7.9M	9.1M	9.6M
Other Stockholder Equity	615.3M	633.8M	652.2M	788.7M	907.0M	952.4M
Total Liab	185.8M	116.9M	113.9M	160.9M	185.1M	194.3M
Property Plant And Equipment Gross	13.9M	11.8M	17.9M	38.5M	44.2M	46.5M
Total Current Assets	246.2M	191.3M	129.6M	232.2M	267.1M	280.4M
Short Term Debt	11.0M	3.2M	3.2M	1.6M	1.8M	1.7M
Common Stock	4K	5K	8K	12K	13.8K	14.5K
Property Plant Equipment	10.2M	8.1M	11.8M	9.9M	11.3M	7.1M
Net Tangible Assets	(3.6M)	76.1M	88.0M	35.4M	31.8M	40.7M
Retained Earnings Total Equity	(383.6M)	(539.3M)	(545.8M)	(616.8M)	(555.2M)	(527.4M)
Long Term Debt Total	49.3M	41.2M	51.4M	54.0M	62.1M	33.7M
Capital Surpluse	380.0M	615.3M	633.8M	652.2M	750.0M	424.2M
Inventory	1.2M	1.3M	2.0M	2.3M	2.7M	2.8M
Deferred Long Term Liab	12.1M	98.3M	20.2M	6.4M	7.3M	6.9M
Non Current Liabilities Other	19.5M	18.9M	22.2M	108K	124.2K	118.0K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:

How To Invest In Ocular

Details

Is Ocular Stock a good investment?

Details

What is Ocular Therapeutix's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocular Therapeutix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. If investors know Ocular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocular Therapeutix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.29)

Revenue Per Share

0.447

Quarterly Revenue Growth

0.023

Return On Assets

(0.27)

Return On Equity

(0.97)

The market value of Ocular Therapeutix is measured differently than its book value, which is the value of Ocular that is recorded on the company's balance sheet. Investors also form their own opinion of Ocular Therapeutix's value that differs from its market value or its book value, called intrinsic value, which is Ocular Therapeutix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocular Therapeutix's market value can be influenced by many factors that don't directly affect Ocular Therapeutix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ocular Therapeutix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocular Therapeutix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ocular Deferred Long Term Liab vs Net Tangible Assets Analysis

Deferred Long Term Liab vs Net Tangible Assets

Deferred Long Term Liab vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Net Tangible Assets

Ocular Therapeutix fundamental ratios Correlations

Ocular Therapeutix Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ocular Therapeutix fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.99	Total Assets
Long Term Debt	+ 0.99	Short Long Term Debt Total
Net Receivables	+ 0.99	Other Current Liab
Other Stockholder Equity	+ 0.99	Common Stock Shares Outstanding

Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Retained Earnings	- 0.95	Total Current Liabilities
Retained Earnings	- 0.95	Short Long Term Debt Total
Long Term Debt	- 0.94	Retained Earnings
Retained Earnings	- 0.94	Property Plant And Equipment Net